Record-breaking pharma M&A value disguises plummeting deal-making activity
Abundant biotech funding seems to be empowering small- and medium-sized IP rights holders and driving down acquisition and licensing volume
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Register now
Subscribe and start reading now
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.
Subscribe now